COVID-19 Resources: Guidance for Chan Researchers

Featured news and announcements

Check out the School’s updated Coronavirus website, which showcases our researchers’ work on the front lines of the global response to COVID-19:
https://www.hsph.harvard.edu/coronavirus/.

COVID FAQs and new funding opportunities for the period 08/26/20 – 08/31/20

As COVID-19 spreads across the globe, new research funding opportunities are cropping up, along with questions regarding how COVID-19-related disruptions to research might affect current federal funding. Answers to many of those questions and information on a variety of new funding opportunities is provided by clicking on the related link below:

1. Covid-19 research funding opportunities
2. COVID-19 related research news and policy updates
3. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19
4. Free access and free services for researchers related to COVID-19
5. COVID-19 news by Chan faculty

1. COVID-19 research funding opportunities

Internal COVID-19 Funding Announcements

Non-federal COVID-19 Funding Announcements

*NEW: International Lung Cancer Foundation: The Lung Ambition Alliance
Deadline: September 15, 2020
The purpose of this program is to fund groundbreaking research related to COVID-19 infected lung cancer patients. The intent of the support is to allow junior faculty researchers, as defined as fewer than 7 years in a faculty position after training, to obtain preliminary data that will enable them to successfully compete for national peer-reviewed grant support

Fundación MAPFRE (MAPFRE Foundation): Ignacio H. de Larramendi Research Grants
Deadline: October 30, 2020
The Ignacio H. de Larramendi Research Grants program provides support for research in the area of health promotion. Interests include strategies for habit change (prevention of obesity and promotion of physical activity), patient education, physical injury assessment, and health management (clinical quality and safety). In this call, special attention will be given to the projects which, while taking into account the previous topics, incorporate aspects related to COVID-19 such as: reducing infections, self-care and the culture of self-protection, relationship between previous health status (lifestyle) and morbimortality,
COVID-19 and mental health, etc. Academic and professional researchers and research teams around the world are eligible to apply.

Workers' Compensation Board of British Columbia (WorkSafeBC or WCB): 2020 Specific Priorities and Impacts of COVID-19
Deadline: October 31 2020
Specific Priorities grants support research of relevance to WorkSafeBC, workers and workplaces to address key questions in occupational health and safety and recovery and return-to work of injured workers. The purpose of this RFP is to solicit research proposals relating to the changing nature of work and the work environment.

Seoul Innovation QuickFire Challenge: Healthcare for the New Normal
Deadline: 31, 2020
Johnson & Johnson Innovation—JLABS, in collaboration with Seoul Metropolitan Government, Korea Health Industry Development Institute, and Janssen Korea Ltd., is launching the Seoul Innovation QuickFire Challenge for Healthcare in the New Normal. The Challenge seeks the best ideas aiming to address and enable potential healthcare solutions in the post-COVID era. Interests include health technologies, e-health platforms, rapid diagnostics for rare diseases, companion diagnostics for oncology, and smart systems for vaccine distribution and patient adherence.

European Commission: Enhancing Civil Society Organizations' Capacities in Response to COVID-19 in India
Deadline: September 1, 2020
The European Commission has issued a call for proposals that aims to support Indian civil society organizations' (CSOs) efforts in mitigating the social and economic impacts of the COVID-19 pandemic among the most vulnerable populations in India. This may be achieved through ensuring access to public entitlements, social protection, promotion of skills and employment, and advocating for public policies.

March of Dimes Foundation: 2020 COVID-19 Fund
Deadline: September 4, 2020
Currently, the health threats that moms and babies face include the COVID-19 viral pandemic where pregnant women and babies are at risk of infection and subsequent complications. The March of Dimes COVID-19 Fund was created to support the urgent need for COVID-19 specific research in maternal-child health, to help women preparing for childbirth, the families caring for a newborn, and healthcare providers during this time.

Collaborative Initiative for Paediatric HIV Education and Research (CIPHER): CIHPER Grant Programme (2020/2021)
Deadline: October 31, 2020
This grant focuses on service delivery for HIV and related co-infections for paediatric and adolescent populations in resource-limited settings, including research on: 1) The impact of the COVID-19 pandemic on HIV and related co-infections service delivery; and 2) Community interventions to improve outcomes along the HIV cascade.

The Boehringer Ingelheim: IIS Program
Deadline: continuous
This program is offered to all qualified academic and community-based scientists or consortia who are interested in independently proposing and conducting their own research to evaluate potential clinical
and non-clinical investigations involving COVID-19 related matters including safety, clinical outcomes, antiviral effects, or antithrombotic benefits.

**The American Lung Association: COVID-19 and Emerging Respiratory Viruses Research Award**
Deadline: May 30, 2021
This award invites applications for its COVID-19 and emerging respiratory viruses research award. This supports research focusing on emerging respiratory pathogens like SARS-CoV-2. Projects must directly be related to COVID-19 or other viral respiratory threats that may arise in the future.

**WITH Foundation: RFP**
Deadline: September 3, 2020
The WITH Foundation and the American Academy of Developmental Medicine and Dentistry have released a request for proposals to support the development of additional educational materials, implementation models, and research that addresses the challenges primary care providers experience in serving adults with intellectual and developmental disabilities during pandemic or emergency situations.

**UK Robotics: Medical Robotics for Contagious Diseases Challenge**
Deadline: September 30, 2020
The COVID-19 pandemic offers a unique opportunity to galvanize medical robot technologies, as they play an increasingly major role in combating contagious diseases. This new international challenge is aimed at entries that could offer solutions as part of a multi-faceted response to this and future global pandemics.

**The Global Fund to Fight AIDS, Tuberculosis and Malaria: COVID-19 Response Mechanism**
Deadline: by May 31, 2020 or as soon as possible thereafter.
The COVID-19 Response Mechanism supports countries to respond to COVID-19, mitigate the impact on programs to fight HIV, TB and malaria, and initiate urgent improvements in health and community systems. With an initial allocation of $500 million, the COVID-19 Response Mechanism leverages the principle of country ownership and allows countries to request funding for control and containment, including laboratory networks, supply chains, and community-led response. Eligible applicants include those countries that directly receive Global Fund financing. All funding requests must be coordinated and submitted by the Country Coordinating Mechanism.

**Innovation for Poverty Action: Peace & Recovery Program: COVID-19 response**
Deadline: Rolling
For time-sensitive research or additions to research projects that study or support the COVID-19 response. This funding window could support projects that:
- Generate new data to directly inform the COVID-19 response of committed partners
- Evaluate interventions that are expected to improve COVID-19 response or recovery
- Add a module to an existing survey in order to track COVID-19 exposure or response
- Add a treatment arm that may support communities' resiliency in response to COVID-19
- Anonymize, curate, and share already-collected data quickly so that it can be used for decision-making by the humanitarian community
- Conduct a “downstream survey” that follows up on a sample that participated in an already-completed randomized trial in order to identify whether the intervention studied has an impact on the communities' response to COVID-19
Successful applicants will have a research team or staff that has the necessary experience to study the emergency response. As a result, interdisciplinary teams are encouraged.

Mercatus Center: COVID-19 Response: A Call for Ideas
Deadline: Rolling
The Mercatus Center, building on its COVID-19 policy brief series, welcomes proposals for policy briefs, working papers, and articles that address the next round of challenges facing the United States and other countries in the response to the pandemic, specifically, in the topics of restarting and reopening, institutional challenges, health and science policy, economic and regulatory policy, and monetary policy.

Engineering and Physical Sciences Research Council (EPSRC) - United Kingdom
Deadline: September 30, 2020
The Engineering and Physical Sciences Research Council, through the UK-RAS Network and in collaboration with Imperial College London, Wellcome, KUKA and Intuitive Surgical, invites submissions for its medical robotics for contagious diseases challenge. This seeks innovative ideas that could aid in the response to the current COVID-19 pandemic and future global pandemics. The COVID-19 pandemic offers a unique opportunity to galvanize medical robot technologies, as they play an increasingly major role in combating contagious diseases.

Biogen Foundation: COVID-19 Relief Effort
Deadline: Unspecified (accepting applications)
The Biogen Foundation has committed $10M to aid in COVID-19 relief efforts around the world. At this time, the Biogen Foundation’s COVID-19 relief efforts are focused on the following categories: Expanding and ensuring access to testing; Easing the burden on healthcare systems and healthcare workers; Providing food and necessities for our most vulnerable populations.

COVID-19 Early Treatment Fund (CETF) and Rockefeller Philanthropy Advisors
Deadline: Not announced
This program funds initiatives that focus on treating outpatients to prevent hospitalization. CETF is narrowly focused on ensuring that outpatient trials for four drugs are successful (Peginterferon lambda, Favipiravir, Camostate mesylate, and Remdesivir). That means we’ll provide funding, help improve study protocols, find ways to manufacture drugs in short supply and do whatever it takes to move these medicines forward.

Draper Richards Kaplan: Coronavirus Urgent Response Initiative
Deadline: Not specified
This initiative supports ideas that are tackling the most acute and time-critical social problems caused by the Covid-19 pandemic right now. DRK wants to help jumpstart projects that can realistically deploy within 30 days.

Ferring COVID-19 Investigational Grants in Reproductive Medicine and Maternal Health
Deadline: October 31, 2020
Ferring is interested in funding exploratory, basic, and clinical research grants to collect data and expand knowledge about the effects of SARS-CoV-2 on reproduction, pregnancy, and fetal/neonatal health. The Ferring COVID-19 Investigational Grants in Reproductive Medicine and Maternal Health (RMMH) are designed to provide funding to gather data related to IVF programs during the COVID-19 pandemic including but not limited to: Follow-up data on infected pregnant patients at different gestational stages, including spontaneous pregnancies; Data on the outcome of ongoing fertility care; Data on
gametes/embryos, fresh or frozen, from patients exposed to SARS-CoV-2; and Other information related to fertility outcomes.

American Heart Association: Rapid Response Grant and its Cardiovascular Impact
Deadline: April 06, 2021
This grant invites cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19. Because of the urgency of this issue, innovative, highly impactful short-term proposals (9-12 months), which can show progress within the period of this award, are sought.

Robert Wood Johnson: Pioneering Ideas: Exploring the Future to Build a Culture of Health
Deadline: Continuous
This award seeks ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. Additionally, we welcome ideas that might fall outside of these four focus areas, but which offer unique approaches to advancing health equity and our progress toward a Culture of Health. While this call for proposals is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, we recognize the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

Amgen Foundation: COVID-19 Relief Support
Deadline: none
The Amgen Foundation is dedicated to combating this pandemic by working across several fronts to apply their unique strengths in genetics, immunology, and antibody engineering to prevent and treat COVID-19. The Foundation’s COVID-19 Relief Support program is dedicated to supporting patients and communities in the fight against COVID-19. Support is provided in the U.S., including Puerto Rico.

Merck KGaA: Research Grant for Pandemic Preparedness
Deadline: Rolling
This grant seeks proposals that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections.

Patient-Centered Outcomes Research Institute: Enhancements to existing Research Projects and Engagement Awards
Deadline: Rolling
PCORI is requesting enhancements to existing Research Projects and Engagement Awards that can be initiated quickly to influence the outcome of the current pandemic and that have some relationship to the original award, using existing teams that are currently funded: COVID-19-Related Enhancements to Existing PCORI-Funded Research Projects; COVID-19-Related Enhancements to Existing PCORI-Funded Engagement Awards who has funding

Fast Grants: Fast Funding for COVID-19 Science
Deadline: Not announced
These grants are for scientists at an academic institution currently working on a COVID-19 related project and in need of funding. Fast Grants are $10k to $500k and decisions are made in under 48 hours.
Mozzila: COVID-19 Solutions Fund
Deadline: Rolling
The fund will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related...

California Institute for Regenerative Medicine (CIRM)
Deadline: Open on a bi-monthly basis.
The CIRM has allocated $5 million in funding for peer-reviewed regenerative medicine and stem cell research that could quickly advance treatments for COVID-19. Support is provided for promising discovery, preclinical, and clinical trial stage projects.

Nellie Mae Education Foundation: Racism is a Virus Too
Deadline: Rolling basis until resources are exhausted
The Nellie Mae Education Foundation created a rapid response fund to respond to the hate crimes and bias against Asian American communities in New England resulting from COVID-19.

Omidyar Network India: Rapid Response Funding for COVID-19
Deadline: Not announced
The Omidyar Network India has announced a rapid response window to fund proposals that support the lower 60% of India’s income distribution in managing and mitigating the challenges that come with Covid-19. Support is provided for initiatives that strengthen containment, detection and treatment, support crisis management capabilities, and enhance resilience and recovery in the wake of Covid-19.

Open Road Alliance
Deadline: Not announced
The Open Road Alliance is offering charitable grants to organizations responding directly to COVID-19, with priority given to organizations and activities that have a clear and direct role in ‘flattening the curve’ and thus limiting, shortening, or minimizing the economic and social, as well as health effects of the pandemic. Loans are also available to organizations affected by COVID-19, including those with lost event revenue, those delivering vital community services, and social enterprises.

Bill & Melinda Gates Foundation, Wellcome and Mastercard: COVID-19 Therapeutics Accelerator
Deadline: varies
This initiative speeds development and access to therapies for COVID-19 by coordinate R&D efforts and removing barriers to drug development and scale-up to address the epidemic. Gokhan

2. Federal COVID-19 Funding Announcements

National Institutes of Health:

NIH: Research on the Health of Women of Understudied, Underrepresented and Underreported (U3) Populations (Admin Supp Clinical Trial Optional)
Deadline: rolling through January 21, 2021
ORWH is encouraging application submissions and is seeking to support studies on the SARS-CoV-2 virus or COVID-19 disease in alignment with efforts across NIH to develop and implement effective therapeutics and vaccines and to accelerate research on technologies to validate and improve programs
that will overcome barriers and increase uptake of effective therapeutics and vaccines at the point of care. Within the focus of this funding opportunity announcement, research topics of interest could include investigating the risk factors associated with COVID-19 disease prevalence among NIH-designated health disparity populations, women living in underserved rural or urban settings, pregnant and lactating women, women frontline healthcare workers, women with low socioeconomic status, and women experiencing homelessness or having justice system involvement.

Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed) (PAR-20-178)
Deadline: Rolling
This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

NIH: Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)
Deadline: 09-19-2020

NIH: Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
Deadline: 10-01-2020

NIH: Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)
Deadline: September 16, 2020

NIH: Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kids) (R61/R33 Clinical Trial Optional)
Deadline: October 1, 2020

NIH: Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)
Deadline: 09-16-2020

NIH: Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 from Skin and the Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)
Deadline: September 19, 2020

NIH: Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 from Skin and the Oral Cavity (R44 Clinical Trial Not Allowed)
Deadline: September 19, 2020

NIH: Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)
Deadline: September 19, 2020

NIH: Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)
Deadline: 09-16-2020
NIH: Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)
Deadline: January 24, 2021

NIH: Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)
Deadline: December 17, 2020
The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.

NIH: Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)
Deadline: 8/20/20; 12/2/20: 3/2/21
Focuses on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.

NIH: Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required) (PAR-20-234)
Deadlines: July 1, 2020; 3, 2020; September 1, 2020; October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; and February 1, 2021.
This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19).

NIH: Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)
Deadline: March 17, 2021
This funding opportunity announcement (FOA) solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. Both animal and human subjects research projects are welcome. Researchers proposing basic science experimental studies involving human participants should consider this FOA’s companion for basic experimental studies with humans.

NIH: Rapid Acceleration of Diagnostics (RADx) Initiative for COVID-19
Deadline: rolling
NIBIB is providing substantial support to accelerate the development, validation, and commercialization of innovative point-of-care and home-based tests, as well as improvements to clinical laboratory tests, that can directly detect SARS-CoV-2, the virus that causes COVID-19. NIBIB will support the full range of
product development including commercialization and product distribution. Project proposals accepted through online RADx portal.

**NIH Notices of Special Interest:**

**NIH: Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities**
Deadline: October 5, 2020
The purpose of this Notice of Special Interest is to support investigative and collaborative research focused on developing and evaluating simulation modeling and systems science to understand and address minority health and health disparities including the burden related to the recent COVID-19 disease outbreaks.

**NIH: Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates against SARS-CoV-2**
Deadline: September 1, 2020
This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2.

**NIH: Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Health Need (NOT-TR-20-029)**
Deadline: November 11, 2020
The National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the need for projects that address the coronavirus disease 2019 (COVID-19) Public Health Emergency. The Clinical and Translational Science Award (CTSA) Program is uniquely qualified to contribute to these efforts. NCATS is soliciting applications for Administrative Supplements (through PA-18-591) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients.

**NIH: Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-120)**
Deadline: September 9, 2020
This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

**NIH: Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations (NOT-OD-20-119)**
Deadline: September 9, 2020
This Notice of Special Interest (NOSI) highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

**NIH: Notice of Special Interest: Competitive and Administrative Supplements for Community Interventions to Address the Consequences of the COVID-19 Pandemic for Health Disparity and Vulnerable Populations (R01-Clinical Trial Optional) (NOT-MD-20-023)**

**Deadline: Rolling through December 15, 2020**

This Notice encourages investigators to acquire and leverage partnerships with key stakeholders to test community interventions to ameliorate the impact of psychosocial, sociocultural, behavioral, and socioeconomic consequences of COVID-19 on the health of populations known to experience health disparities and other vulnerable populations. Projects may evaluate existing or ongoing community-based programs or policies (i.e., natural experiments) or prospectively test new or adapted interventions. Projects that do not solely target individuals but also address the upstream determinants that influence individual functioning and health outcomes will be strongly encouraged.

**NIH: Notice of Special Interest (NOSI): NIDCD is interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders (NOT-DC-20-008)**

**Deadline: October 05, 2020**

NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.


**Deadline: TBA**

NIMH has already made a significant investment in a data repository to hold human subjects data related to mental illness and related fields. This repository allows data from multiple sources to be aggregated and easily accessed by the research community. However, the data repository is most useful when research laboratories collect data using the same set of data elements. With this Notice, NIMH offers guidance on the use of consensus-derived common data elements (CDEs) pertaining to mental health outcomes that were previously discussed in NOT-MH-15-009 and a set of newly available measures regarding experiences during the COVID-19 public health emergency and exposures to the SARS-CoV-2 virus (the virus that causes COVID-19). The goal of this Notice is to reduce proliferation of one-off survey items and to facilitate data integration, collaboration, and comparisons across data sets.

**NIH: Notice of Special Interest (NOSI): Availability of Administrative Supplements & Urgent Competitive Revisions to NCCIH Grants for Natural Product Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) & Coronavirus Disease 2019 (COVID-19) (NOT-AT-20-012)**

**Deadline: Rolling**
To rapidly establish scientific evidence and/or elucidate the mechanism of action of natural product–based remedies for SARS-CoV-2 and COVID-19, NCCIH is encouraging the submission of applications for administrative supplements or competitive revisions of active NCCIH grants.

NIH: Notice of Change to Eligible Activity Codes for NOT-NS-20-051 "Notice of Special Interest: Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System" (NOT-NS-20-074)
Deadline: April 15, 2021
The purpose of this notice is to inform interested applicants of a change to the eligible activity codes for NOT-NS-20-051 "Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System". Effective immediately, the RF1 activity code will be added as an eligible activity code to NOT-NS-20-051, for applications submitted to both, PA-18-591 "Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional) " and PA-18-935 "Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional)".

NIH: Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System (NOT-NS-20-051)
Deadline: May 1, 2020-April 15, 2021
NINDS is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Notice of Information: Contributing to the Global COVID-19 Crisis Response by Allowing Some NCI-supported Projects to be Redirected to COVID-19-related Research During the Crisis (NOT-CA-20-054)
Deadline: Not announced
The COVID-19 pandemic is a global health crisis that has engaged the attention of researchers who want to be able to contribute their expertise and resources toward a better understanding of the impacts of SARS-CoV-2 infection and COVID-19 disease on cancer patients’ disease progression, response to therapy, care delivery, or survivorship.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials
Deadline: October 6, 2020
NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19. It is strongly recommended that the parent activity code be one of the following: P01, R01, R33, R41, R42, R43, R44, U01, U24, U54, UH3, or UM1. Topics of specific interest to the NHLBI include the safety and efficacy of interventions for primary prevention and/or treatment of COVID-19, associated clinical phenotypes, and surrogate outcomes, relevant to heart, lung, and blood (HLB) diseases.
NOSI: Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System

Deadline: April 14, 2021
This NOSI highlights the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects on the nervous system of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Research of interest must fall within NINDS’s scientific mission, which is to support basic, translational, and clinical neuroscience research to expand fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

Deadline: May 04, 2020 through November 11, 2020
NCATS is soliciting applications for Administrative Supplements (through PA-18-591) and Emergency Competitive Revisions (through PA-20-135) from current Clinical and Translational Science Award (CTSA) UL1 and U24 award recipients.

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)
Deadline: May 1, 2021
NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address the following research areas of interest: Division of Aging Biology (DAB) Research Interests; Division of Neuroscience (DN) Research Interests; Division of Geriatrics and Clinical Gerontology (DGCG) Research Interests; Division of Behavioral and Social Research (DBSR) Research Interests.

Notice of Special Interest: Availability of Administrative Supplements and Competitive Revision Supplements on Coronavirus Disease 2019 (COVID-19) within the Mission of NIAAA
Deadline: through April 16, 2021
This NOSI encourages applications to assess the impact of alcohol as a biological contributor to COVID-19 outcomes, to assess behavioral, social, and economic consequences of the pandemic and to assess the responses that the pandemic has provoked as they relate to alcohol consumption and related outcomes.

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)
Applications received after 5:00 PM on July 15, 2020 may be held for consideration in Fiscal Year 2021 and not be eligible for funding before October 2021
The National Institute on Minority Health and Health Disparities seeks research on the impact of the novel Coronavirus (SARS-CoV-2) pandemic causing COVID-19 disease outbreaks and the resulting disruptions on individual and social wellbeing, health services use, and health outcomes for NIH-designated health disparity populations.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions to Existing NIH Grants and Cooperative Agreements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-017)
Deadline: Rolling - May 15, 2020- January 26, 2022
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements for Tissue Chips Research on the 2019 Novel Coronavirus (NOT-TR-20-016)
Deadline: Rolling - May 15, 2020 through January 25, 2022
For research in the use of microphysiological systems or tissue chips in collecting and examining data on the risks and outcomes for COVID-19 infection, and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Deadline: Rolling - March 27, 2020-April 16, 2021
For research to provide an evidence base for how a disrupted workforce may adequately respond/adapt to and maintain services or provide additional care for new or increasing mental health needs, as well as to learn about the effects of the virus and public health measures to prevent spread of COVID-19 that may have an impact on mental health. Research addressing the intersection of COVID-19, mental health, and HIV treatment and prevention are also of interest to NIMH.

Deadline: Rolling - May 01, 2020-May 04, 2021
For research to understand the impact of environmental exposures on (COVID-19) and its causative agent, the severe acute respiratory syndrome coronavirus. NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies.

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)
Deadline: October 17, 2020
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 novel coronavirus (SARS-CoV-2) and the disease it causes, i.e., “coronavirus disease 2019” (COVID-19). NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. NCATS is soliciting applications to PAR-17-465, PAR-18-462, and PAR-18-332.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Deadline: February 6, 2021
There is an urgent public health need to better understand SARS-CoV-2, particularly to improve the predictive quality of existing models of spread, diagnostics for measurement of transmission, susceptibility and recovery, and development of therapeutic interventions. NIGMS will accept the submission of applications for Competitive Revisions to active grants to address only the following research areas of interest:
Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).

Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).

Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)
Deadline: March 31, 2021
NIDA is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on the 2019 Novel Coronavirus (2019-nCoV, also known as COVID-19). NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications in response to this NOSI must be submitted using the following targeted funding opportunity: PA-18-935 Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement - Clinical Trial Optional); and PA-18-591 Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional).

Notice of Special Interest regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Deadline: Applications accepted on a rolling basis from February 6, 2020 through February 6, 2021
NIAID and NIGMS highlight the urgent need for research on the 2019 novel Coronavirus: NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV; and NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronaviruses and related pathogens.

Notice of Special Interest: Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019
Deadline: October 6, 2020
NHLBI is issuing this Notice of Special Interest to highlight the urgent need for research on Coronavirus Disease 2019 and on biological effects of its causative agent, the severe acute respiratory syndrome. Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

NIH: Notice of Special Interest regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus
Deadline: Applications will be accepted on a rolling basis through March 31, 2021
NIDA is issuing this notice to highlight the urgent need for research on the 2019 Novel Coronavirus. NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Other federal agencies:

DHHS Administration for Community Living/: Aging and Disability Resource Center/No Wrong Door System Funding Opportunity: Critical Relief Funds for COVID-19 Pandemic Response
Deadline: None specified
The purpose of this emergency FOA is to support capacity and resource allocation at the state, local and territorial level to ensure coordination across agencies and support immediate response to urgent needs resulting from COVID-19. Funding will enable states and territories to support ADRCs in providing critical access functions to those populations most at risk of COVID-19 and mitigate adverse effects resulting from this national pandemic such as social isolation, limited access to nutritional supports and personal care services, etc. Additionally, funds would enable ADRCs to enhance and increase virtual access to services such as utilizing telehealth technologies to engage with health care practitioners and case managers.

**UK Ministry of Defense/Defense and Security Accelerator: Point of Care Diagnostics at the Front Line**
Deadline: September 26, 2020
This call supports diagnostics technologies that provide information to enable clinicians to earlier diagnose and ultimately treat individuals exposed to chemical and biological hazards. Proposals should address technologies that would enable the diagnosis of individuals exposed to a wide variety of agents, regardless of starting technology readiness level, up to TRL 6. These technologies can be targeted at the agents themselves or at host biomarkers that change as a result of exposure.

**DOS: U.S. Mission to India - COVID-19 Small Grants Program**
Deadline: September 30, 2020
This funding opportunity seeks to support effective coalitions that will bolster and leverage U.S.-India collaboration across a range of fields to fight COVID-19, in India and globally. Potential grantees should be able to implement a small-grants program to promote innovation in addressing COVID-19, encourage partnerships between U.S. and Indian institutions and organizations in combating COVID-19, and facilitate joint action that makes a difference against the disease. The grant will provide resources for a grantee to manage and administer small grants to stakeholders from government organizations, non-profits, think tanks, academic institutions, incubators and accelerators, in close coordination with the U.S. Mission to India. The grantee will be required to solicit proposals that contribute to and/or build upon initiatives that counter the impact of COVID-19 on Indian society, U.S.-India cooperation, and wider communities across the Indo-Pacific region.

**HHS: Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed) (PAR-20-177)**
Deadline: April 30, 2021
This opportunity provides an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).

**HHS: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional)**
Deadline: September 25, 2020
This FOA solicits competitive revision applications to support the demonstration, and/or dissemination, and/or implementation of highly innovative and impactful translational science projects that address the goals of the CTSA Program that are beyond the original scope of the approved project. Projects will be considered for an increase in support for an expansion of the parent project’s approved scope.

**NSF: Dear Colleague Letter 20-052 re Corona Virus Proposals**
Deadline: varies
NSF is accepting proposals to model, track, inform, educate, and prevent the spread of Coronavirus through its existing funding opportunities. NSF invites researchers to use the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency with regard to availability of or access to data, facilities or specialized equipment as well as quick-response research on natural or anthropogenic disasters and similar unanticipated events. Visit NSF, Dear Colleague 20-053 for Coronavirus proposal FAQs and conditions and process for proposal deadline extension.

NSF-Office of Advanced Cyberinfrastructure (OAC), Dear Colleague Letter 20-055
Deadline: varies
OAC is inviting Rapid Response Research (RAPID) funding mechanism proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

HHS: Development of Medical Products for Novel Coronavirus: Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
Deadline: October 31, 2020
This amendment solicits proposals for advanced development and licensure of COVID-19 diagnostics, vaccines, or medicines such as therapeutics or antivirals.

HHS/CDC: Prototype Development to Combat Novel Coronavirus Disease COVID-19
Deadline: April 30, 2020
The Government seeks to rapidly accelerate the inquiry, testing, and fielding of new 21st century capabilities, employing novel technologies and approaches to the detection of exposure, prevention, containment and treatment of COVID-19 and future emerging threats.

DOE: Invitation for COVID-19 Scientific Questions (DOE Resources)
Deadline: Ongoing
The Department encourages scientific questions that underpin COVID-19 response and that the research community may answer using DOE user facilities, computational resources, and enabling infrastructure. Please send research questions that the scientific community may address with DOE resources by email to SC.DCL@science.doe.gov.

USAID/Bangladesh and the Private Sector: Partnering to Fight COVID-19 Agency for International Development
Deadline: April 29, 2021
The goal of the USAID Bangladesh and the Private Sector: Partnering to Fight COVID-19 program is to provide a medium through which organizations can work with USAID and the private sector to build Global Development Alliances (GDAs) that will: a) respond to the current outbreak of COVID-19 in Bangladesh; b) address important business interests and objectives; and c) advance USAID’s strategic priorities and objectives.

Previously Announced NIH Limited Submission Opportunities

Limited Submission - NIH: Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)
Sponsor Deadline: September 19, 2020
Limited Submission - NIH: Emergency Awards: Exosome-based Non-traditional Technologies towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)
Sponsor Deadline: September 19, 2020

Limited Submission - NIH Director’s Emergency Early Independence Awards (DP5 Clinical Trial Optional) (RFA-RM-20-021)
Sponsor deadline: September 4, 2020

Limited Submission - NIH Director’s Emergency Transformative Research Awards (R01 Clinical Trial Optional) (RFA-RM-20-020)
Sponsor deadline: September 4, 2020

3. COVID-19 related research news and policy updates

A few of the provisions in the third COVID-19 relief/response package that might be of particular interest to researchers is below. To read more, please download a section-by-section summary and the legislative text.

- NIST - $6 million to provide continuity of operations and to conduct research and measurement science to support the testing and treatment of coronavirus. Page 622 of the legislative text.
- NSF - $75 million to support research at molecular, cellular, physiological and ecological levels to better understand coronavirus genetics, modes of action, transmission, virulence, and population dynamics. It is expected that many of these funds will be available through the Rapid Response Research funding mechanism. Read Dear Colleague Letter here. Page 629.
- DOE Office of Science - $99.5 million for costs related to equipment, personnel, and operations to support research on the coronavirus, including support to provide access to user facilities. Page 654.
- EPA S&T - $1.5 million to support research efforts regarding coronavirus – and specifically, research on methods to reduce risks from environmental transmission via contaminated surfaces. Page 713.
- CDC - $4.3 billion to support federal, state, and local public health agencies to prevent, prepare for and respond to the coronavirus. Included in that amount is $500 million for global disease detection and emergency response, $500 million for public health data surveillance and analytics infrastructure modernization, and $300 million for the Infectious Diseases Rapid Response Reserve Fund, which supports immediate response activities during outbreaks. Page 728.
- NIH - The bill includes $945 million to support research and expand on prior research plans, including developing an improved understanding of the prevalence of COVID-19, its transmission and the natural history of infection, and novel approaches to diagnosing the disease and past infection, and developing countermeasures for the prevention and treatment of its various stages. Of this total, $103 million is allocated for NHLBI, $706 million NIAID, $60 million NIBIB, $36 million NCATS, $30 million OD, and $10 million for National Library of Medicine. When combined with the first supplemental, Congress has provided $1.78 billion for NIH research on COVID 19. Page 730.
- BARDA (Biomedical Advanced Research and Development Authority) - At least $3.5 billion to advance construction, manufacturing, and purchase of vaccines and therapeutics to the American people.
- NASA - $60 million to support NASA with resources for operational adjustments associated with mission delays caused by NASA center closures related to coronavirus. Page 628. Also, the package includes a number of health-related authorizations, including the HRSA health professionals and nursing workforce development programs.
4. Guidance for federally-funded clinical trials and human subjects studies affected by COVID-19

NIH
- Chart showing the various flexibilities provided for the current and next round of peer review.
- Considerations for New and Ongoing Human Subjects Research During the COVID-19 Public Health Emergency under Human Subjects
- Coronavirus Update: Guidance for Peer Reviewers
- OHRP Guidance on COVID-19 under Human Subjects and Clinical Trials
- NHLBI Announces Availability of Frequently Asked Questions (FAQs) for NOT-HL-20-757, Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-HL-20-759)
- notice on Guidance for Cost-Related Flexibilities Available to Support of Competitive Research (SCORE) Award Recipients Affected by COVID-19
- Virtual NIH Activities for Trainees Outside the NIH
- Animal Welfare: COVID-19 Pandemic Contingency Planning for Animal Care and Use Programs
- Coronavirus Disease 2019 (COVID-19): Information for NIH Applicants and Recipients of NIH Funding. The page now includes a link to page update history so you can easily see what’s new.
- New guidance of flexibilities for awardee, students and conference funding during COVID-19 period
- FAQs including new section on Training, Fellowship and Career Development Awards
- An FAQ to address questions regarding proposal submission and award management
- A lenient late-application policy for those who are unable to meet application deadlines due to the COVID-19 emergency
- NIH grant recipients may extend the final budget period of the approved project on active grants one time for up to 12 months without requesting prior approval from NIH

Other Federal Guidance
- USAMRAA’s Supplemental Guidance on Administrative Flexibilities for Grants and Cooperative Agreements in Response to COVID-19 Pandemic
- Frequently Asked Questions (FAQs) published by The Department of Defense (DoD)

5. Free access and free services for researchers related to COVID-19

- NIH VideoCast is a free National Library of Medicine webinar for researchers to learn how to share, discover, and cite COVID-19 data and code in generalist repositories.
- NIH Resource to Analyze (COVID-19) Literature: The COVID Portfolio Tool
  NIH Office of Portfolio Analysis (OPA) has built a comprehensive listing of (COVID-19) publications, available to the public. The portfolio is updated daily and draws from PubMed resources for citations and abstracts of published biomedical literature.
- The COVID-19 High Performance Computing (HPC) Consortium is a unique private-public effort spearheaded by the White House Office of Science and Technology Policy, the U.S. Department of Energy and IBM to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines.
COVID-19 Collaboration Platform: This platform is a home for RCT protocols that are available for collaboration.

CD2H COVID Case Report Forms and Phenotyping Standards website

The Center for Leading Innovation and Collaboration COVID-19 page

The American Heart Association is working to ensure optimal care for patients with cardiovascular disease who contract coronavirus (COVID-19). Patients with underlying cardiovascular diseases appear to have an increased risk for adverse outcomes with COVID-19. Here are helpful resources for health systems, clinics, care providers, patients and the public.

National Library of Medicine, through its GenBank® sequence database, is providing the biomedical community free and easy access to genome sequences from the novel coronavirus associated with the recent outbreak of pneumonia in Wuhan, China. The outbreak was declared a global health emergency on January 30, 2020 and GenBank® continues to rapidly release data associated with this outbreak as it comes in and welcomes sequence data submissions as well.

Internal: FAS Research Computing has offered to provide enhanced support to Harvard Chan School research related to COVID-19. Examples of support include help with workflow automation to improve efficiency for COVID-19 data analysis, and prioritized assistance for virtual machine requests for hosting a COVID-19 analytic tools website. For more information, please contact the FASRC team via email or attend one of their virtual office hours which are held weekly on Wednesdays from 12 PM to 3 PM.

Open Research Dataset (CORD-19) is a resource of over 45,000 scholarly articles, including over 33,000 with full text, about COVID-19, SARS-CoV-2, and related coronaviruses.

IBM has resources to share — like supercomputing power, virus tracking and an AI assistant to answer citizens’ questions.

LitCovid is a curated literature hub for tracking up-to-date scientific information about the 2019 novel Coronavirus.

The National Institute of Allergy and Infectious Diseases (NIAID) has made 2019 SARS-CoV-2 and other Coronavirus strains and reagents available through its BEI Resources Repository.

The American Journal Experts are offering free language editing and translation services for articles related to coronavirus disease 2019

Sharing research data and findings relevant to the novel coronavirus (COVID-19) outbreak, with NIH as a signatory to the statement Wellcome Trust news, January 31, 2020

The BMJ: Coronavirus

Chongqing VIP Information, a Chinese journal database

Elsevier: Novel coronavirus information center

The Lancet: COVID-19 resource centre

New England Journal of Medicine: free Journal content on coronavirus

Royal Society of Tropical Medicine and Hygiene: Coronavirus free collection

Springer Nature, the publisher of Nature: Novel coronavirus (SARS-CoV-2 and COVID-19)

Wiley Online Library: COVID-19 resources and news

WHO: COVID-19 Course Series - free online courses from OpenWHO

6. COVID-19 news by Chan faculty

- Check out the School’s updated Coronavirus website, which showcases our researchers’ work on the front lines of the global response to COVID-19:
- Find the latest COVID news by Chan faculty here.